Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.
Evolocumab binds PCSK9, increasing low-density lipoprotein cholesterol (LDL-C) receptors and lowering LDL-C. Target-mediated evolocumab elimination is attributable to PCSK9 binding. As circulating PCSK9 and LDL-C levels are primarily regulated by the liver, we compared evolocumab pharmacokinetics, pharmacodynamics, and safety in individuals with and without hepatic impairment. An open-label, parallel-group study evaluated the pharmacokinetics of evolocumab in hepatic-impaired (Child-Pugh Class A or B) or healthy adults. Participants were classified as having no, mild, or moderate hepatic impairment (n = 8/group) and received a single 140-mg evolocumab dose. Assessments of unbound evolocumab and PCSK9 were made predose and postdose. Adverse events were monitored throughout the study. No significant association was observed between baseline PCSK9 and increasing level of hepatic impairment. No difference in extent and time course of PCSK9 or LDL-C reduction was observed despite an apparent decrease in mean unbound evolocumab exposure with increasing hepatic impairment (Jonckheere-Terpstra trend test; maximum serum concentration P = .18; area under the curve P = .09). Maximum reductions were observed in moderately impaired subjects vs healthy individuals: mean maximum serum concentration -34%; mean area under the concentration-time curve (AUC) -47%. On average, unbound PCSK9 serum concentrations fell by >80% at 4 hours after a single evolocumab dose. Mean (95% confidence interval) maximum LDL-C reductions in the healthy, mild, and moderate groups were -57% (-64% to -48%), -70% (-75% to -63%), and -53% (-61% to -43%), respectively. No safety risks were identified. These results support evolocumab use without dose adjustment in patients with active liver disease and mild or moderate hepatic impairment.
Medical Sciences, Amgen, Inc., Thousand Oaks, CA, USA.|AbbVie, North Chicago, IL, USA.
John P
JP
Gibbs
Medical Sciences, Amgen, Inc., Thousand Oaks, CA, USA.|Acerta Pharma, Bellevue, WA, USA.
J Greg
JG
Slatter
Medical Sciences, Amgen, Inc., Thousand Oaks, CA, USA.
Ogo
O
Egbuna
Global Safety, Amgen, Inc., Thousand Oaks, CA, USA.
Michelle
M
Geller
Biostatistics-Internationals, Amgen, Inc., Uxbridge, UK.
Lisa
L
Hamilton
Medical Sciences, Amgen, Inc., Thousand Oaks, CA, USA.|BioMarin Pharmaceutical Inc., San Rafael, CA, USA.
Clapton S
CS
Dias
Medical Sciences, Amgen, Inc., Thousand Oaks, CA, USA.|Gilead Science Inc., Foster City, CA, USA.
Ren Y
RY
Xu
Medical Sciences, Amgen, Inc., Thousand Oaks, CA, USA.
Jessica
J
Johnson
Global Development, Amgen, Inc., Thousand Oaks, CA, USA.
Scott M
SM
Wasserman
Medical Sciences, Amgen, Inc., Thousand Oaks, CA, USA.
Maurice G
MG
Emery
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000097:blood*; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000097:blood*; D007279:Injections, Subcutaneous; D008107:Liver Diseases / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D000071449:Proprotein Convertase 9 / Q000097:blood*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL; D007074:Immunoglobulin G; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; C577155:evolocumab
AMG 145; PCSK9; evolocumab; hepatic impairment; human monoclonal antibody; hypercholesterolemia; low-density lipoprotein; pharmacodynamics; pharmacokinetics
Scand J Gastroenterol. 1972;7(7):623-30
4640052
Br J Clin Pharmacol. 2016 Sep;82(3):696-705
27115790
J Clin Lipidol. 2013 May-Jun;7(3 Suppl):S11-5
23642323
J Am Coll Cardiol. 2014 Jun 17;63(23 ):2541-8
24694531
Drug Discov Today. 2006 Jan;11(1-2):81-8
16478695
Proc R Soc Med. 1977 Dec;70(12):851-5
341172
Clin Ther. 2013 Sep;35(9):1444-51
23891362
Trends Immunol. 2006 Jul;27(7):343-8
16731041
J Clin Immunol. 2013 Jan;33 Suppl 2:S90-4
23271459
J Am Coll Cardiol. 2012 Nov 6;60(19):1888-98
23083772
J Clin Invest. 1970 Apr;49(4):673-80
5443170
Clin Pharmacokinet. 2010 Oct;49(10):633-59
20818831
Circ J. 2014;78(5):1073-82
24662398
Prog Allergy. 1969;13:1-110
4186070
Lancet. 2012 Dec 8;380(9858):1995-2006
23141812
N Engl J Med. 2014 May 8;370(19):1809-19
24678979
MAbs. 2014 Jul-Aug;6(4):1103-13
24859266
Semin Immunopathol. 2013 Jan;35(1):87-100
23111699
Nat Rev Immunol. 2007 Sep;7(9):715-25
17703228
Circulation. 2013 Aug 27;128(9):962-9
23884353
Arch Intern Med. 1997 Apr 14;157(7):792-6
9125012
Drug Metab Dispos. 2014 Nov;42(11):1881-9
25100673
J Am Coll Cardiol. 2014 Jun 17;63(23 ):2531-40
24691094
Vox Sang. 2002 Aug;83 Suppl 1:57-63
12617105
Hepatogastroenterology. 2007 Dec;54(80):2301-5
18265652
Proc Natl Acad Sci U S A. 1996 May 28;93(11):5512-6
8643606
MAbs. 2011 Sep-Oct;3(5):422-30
22048693
Hepatology. 2004 Feb;39(2):574-8
14768020
Clin Pharmacokinet. 2013 Feb;52(2):83-124
23299465
JAMA. 2014 May 14;311(18):1870-82
24825642